IL27 and posterior cortical atrophy: Given the above-mentioned desirable properties in one multifunctional therapeutic agent, we selected IL-27 as our cytokine therapeutic to treat PCa bone metastases, and further enhanced its therapeutic efficacy through the addition of a tumor-targeting and IL-6Rα-antagonistic motif “pepL” (LSLITRL) [7].